Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics on June 8 at an average price of $547.49, generating about $5.2 million and reducing her stake by 19%.
- United Therapeutics reported mixed quarterly results, with EPS of $5.82 missing estimates of $7.00 and revenue of $781.5 million slightly below expectations, though net margin remained strong at 40.62%.
- Wall Street remains broadly bullish on the stock, with 11 Buy ratings and 2 Hold ratings, and a consensus target price of $619.42 despite recent insider selling.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $547.49, for a total transaction of $5,201,155.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,180,462.37. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Price Performance
NASDAQ UTHR opened at $553.14 on Wednesday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market capitalization of $23.48 billion, a price-to-earnings ratio of 20.42, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The company's fifty day moving average price is $569.08 and its two-hundred day moving average price is $520.18.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the company earned $6.63 earnings per share. The company's revenue was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.
Institutional Trading of United Therapeutics
A number of large investors have recently modified their holdings of the company. Avoro Capital Advisors LLC increased its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its holdings in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after acquiring an additional 295,221 shares during the period. Janus Henderson Group PLC increased its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after acquiring an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter worth about $317,617,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
UTHR has been the topic of a number of research reports. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an "outperform" rating and a $700.00 target price for the company. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.42.
Read Our Latest Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
